Amneal Pharmaceuticals (AMRX) Reports Q2 2025 Earnings with Revenue Growth and Margin Improvements
Amneal Pharmaceuticals (AMRX) reported Q2 2025 earnings with total net revenue of $720 million, a 3% increase, driven by new product launches and segment expansion. Adjusted EBITDA rose 13% to $184 million, and adjusted earnings per share increased by 56%, reflecting improved margins and foreign exchange benefits. The company also highlighted strong performance in its specialty segment and new product launches.
Tickers: $AMRX
Topics: earnings EBITDA FDA approval market share product launches revenue growth